Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01280240 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
A Phase 1 study, sponsored by Pharmacosmos A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01280240 is a Phase 1 study that has completed, run by Pharmacosmos A/S. The registered enrollment target is 11 participants.
The verdict
NCT01280240, a Phase 1 study, has completed, sponsored by Pharmacosmos A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 250 mg and 500 mg in patients suffering from Chemotherapy Induced anemia.
Interventions
- DRUG Monofer(R)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01280240
The ClinicalTrials.gov registry entry for NCT01280240 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacosmos A/S, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Monofer(R) is the first listed.
NCT01280240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01280240 about?
NCT01280240 is a clinical study titled "Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia". The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 250 mg and 500 mg in patients suffering from Chemotherapy Induced anemia.
What is the current status of trial NCT01280240?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2012-03. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01280240?
The interventions under investigation include: Monofer(R) (DRUG).
Who is sponsoring clinical trial NCT01280240?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.